Compare NVST & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVST | ARQT |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.3B |
| IPO Year | 2019 | 2020 |
| Metric | NVST | ARQT |
|---|---|---|
| Price | $25.30 | $25.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 7 |
| Target Price | $21.38 | ★ $24.83 |
| AVG Volume (30 Days) | ★ 2.3M | 1.7M |
| Earning Date | 02-05-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $2,621,800,000.00 | $317,929,000.00 |
| Revenue This Year | $7.42 | $85.83 |
| Revenue Next Year | $3.63 | $30.72 |
| P/E Ratio | $293.45 | ★ N/A |
| Revenue Growth | 4.73 | ★ 129.21 |
| 52 Week Low | $14.22 | $11.13 |
| 52 Week High | $25.41 | $31.77 |
| Indicator | NVST | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 76.97 | 38.44 |
| Support Level | $22.72 | $25.35 |
| Resistance Level | $23.97 | $26.93 |
| Average True Range (ATR) | 0.72 | 1.46 |
| MACD | 0.20 | -0.44 |
| Stochastic Oscillator | 96.61 | 12.16 |
Envista Holdings Corp is a dental products company. It develops, manufactures, and markets portfolios of dental consumables, equipment, and services to dental professionals. The company's business consists of two segments; Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment, which derives key revenue, develops, manufactures, and markets dental implant systems, including regenerative solutions, dental prosthetics, and associated treatment software and technologies, as well as orthodontic bracket systems, aligners, and lab products. Geographically, the company generates a majority of its revenue from North America, followed by Western Europe and other developed and emerging markets.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.